<DOC>
	<DOCNO>NCT00271713</DOCNO>
	<brief_summary>Efficacy : To investigate change structural bone property vivo use 3DpQCT ( `` Xtreme '' CT , Scanco ) monthly oral ibandronate therapy woman postmenopausal osteoporosis . Major structural bone parameter determine bone strength predict fracture risk earlier precisely measurable vivo 3DpQCT . Safety : To assess tolerability safety ibandronate therapy</brief_summary>
	<brief_title>Impact Oral Ibandronate 150 mg Monthly Structural Properties Bone Postmenopausal Osteoporosis ( SPIMOS-3D )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Age 60 75 year Menopause &gt; 5 year Spine ( L1 L4 ) hip BMD ≤ 2.0 &gt; 3.5 SD Tscore measure DXA Patients , opinion investigator , able willing comply protocol duration Written inform consent 3DpQCT measurable skeletal site , distal tibia radius Spine hip BMD ≤ 3,5 SD TScore measure DXA Vertebral fracture Multiple ( &gt; 2 ) low trauma peripheral fracture Disease/disorder know influence bone metabolism History major upper gastrointestinal ( GI ) disease Diagnosed malignant disease within previous 10 year Previous treatment bisphoshonate time Treatment fluoride osteoporosis ( dose great 10 mg/day ) within last 12 month , 2 year ( total duration ) Treatment PTH similar agent strontium ranelate time Treatment drug affect bone metabolism within last 6 month Chronic systemic corticosteroid treatment Estrogens , progestins , SERMs , anabolic steroid , active vitamin D analogues/metabolites , calcitonin Calcineurin inhibitor ( e.g . cyclosporine , tacrolimus ) methotrexate Total serum calcium &lt; 2.2 mmol/l &gt; 2.6 mmol/l Vitamin D deficiency ( serum 25hydroxy vitamin D &lt; 12 ng/ ml ) ALT triple upper limit normal range Renal impairment ( serum creatinine &gt; 210 µmol/l ) Contraindications ibandronate , calcium vitamin D Employees Centre Muscle Bone Research , relatives</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>bone structure</keyword>
	<keyword>ibandronate</keyword>
</DOC>